BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 28537894)

  • 1. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
    Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK
    Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
    Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
    Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
    Son CH; Bae JH; Lee HR; Shin DY; Yang K; Park YS
    J Immunother; 2015 Apr; 38(3):107-15. PubMed ID: 25751500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
    Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
    J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
    Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
    Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
    Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy.
    Sato K; Sato N; Xu B; Nakamura Y; Nagaya T; Choyke PL; Hasegawa Y; Kobayashi H
    Sci Transl Med; 2016 Aug; 8(352):352ra110. PubMed ID: 27535621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
    Onda M; Kobayashi K; Pastan I
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
    Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
    Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Mahne AE; Mauze S; Joyce-Shaikh B; Xia J; Bowman EP; Beebe AM; Cua DJ; Jain R
    Cancer Res; 2017 Mar; 77(5):1108-1118. PubMed ID: 28122327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites.
    Chaput N; Darrasse-Jèze G; Bergot AS; Cordier C; Ngo-Abdalla S; Klatzmann D; Azogui O
    J Immunol; 2007 Oct; 179(8):4969-78. PubMed ID: 17911581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
    Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
    Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remodeling of the tumor microenvironment via disrupting Blimp1
    Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
    Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
    Zhu J; Liu JQ; Shi M; Cheng X; Ding M; Zhang JC; Davis JP; Varikuti S; Satoskar AR; Lu L; Pan X; Zheng P; Liu Y; Bai XF
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
    Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
    Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
    Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.